IRD earnings analysis
What we found in IRD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Opus Genetics' Q1 2026 report showed significant underperformance compared to both prior periods and expectations, with revenue of $2.2 million significantly below estimates of $2.9 million and a net loss of $65.5 million versus a much smaller loss in the same quarter last year. The management cites increased operational expenses and lower revenue from collaborations, driving concerns about sustainability despite a robust cash position of $60 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline
- Q1 2026 revenue was $2.2 million, down from $4.4 million in Q1 2025, a decrease of 50%.
- Net Loss Increased
- Net loss for the quarter was $65.5 million, significantly higher than the $8.2 million loss reported for Q1 2025.
- Cash Position Remains Strong
- Cash and cash equivalents were $60 million as of March 31, 2026, providing liquidity for operations.
- R&D Expenses Increased
- Research and Development expenses rose to $10.6 million, compared to $8.0 million in Q1 2025.
- Warrant Liabilities Change
- A fair value loss of $51.4 million was recorded for warrant liabilities in Q1 2026.
- Lower General & Admin Expenses
- General and administrative expenses decreased to $5.9 million from $6.3 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Net Loss
- The company reported a loss of $65.5 million, a deterioration from the prior year's loss of $8.2 million.
- High R&D Expenses
- Research and development costs increased by $2.6 million, leading to unsustainable cash burn.
- Reported Warrant Liabilities Loss
- A loss of $51.4 million related to changes in warrant liabilities points to financial volatility.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.75
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · March 12, 2026
- Opus Genetics (IRD) is a clinical-stage gene therapy company with seven AAV-based programs led by OPGx-LCA5 and OPGx-BEST1 and an FDA-approved Phentolamine ophthalmic product. The 10-K emphasizes constructive regulatory…
- 10-Q · August 13, 2024
- Ocuphire reported license and collaboration revenue of $1,112,000 for the quarter ended June 30, 2024 (vs. $3,674,000 in Q2 2023), a sharp decline. Loss widened: net loss was $7,765,000 (Q2 2024) and loss per share was…
- 10-K · March 8, 2024
- Ocuphire is a clinical‑stage ophthalmic biotech focused on two late‑stage programs: PS (phentolamine ophthalmic solution, marketed as RYZUMVI) which was FDA‑approved in September 2023 and licensed to Viatris, and…
- 10-Q · November 13, 2023
- Ocuphire reported license and collaboration revenue of $11.935M for the three months ended September 30, 2023 and swung to net income of $5.561M (diluted EPS $0.25) versus a net loss of $4.531M a year ago. Cash and cash…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IRD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever